EMA – First gene therapy to treat rare disease Wiskott-Aldrich syndrome
EMA has recommended granting a marketing authorisation in the European Union (EU) for Waskyra (etuvetidigene autotemcel) to treat people aged 6 months and older with Wiskott-Aldrich syndrome (WAS) who have a mutation in the WAS...





